160 related articles for article (PubMed ID: 31305194)
21. Cerebrospinal fluid circulating tumour DNA as a liquid biopsy for central nervous system malignancies.
Escudero L; Martínez-Ricarte F; Seoane J
Curr Opin Neurol; 2020 Dec; 33(6):736-741. PubMed ID: 33177377
[TBL] [Abstract][Full Text] [Related]
22. Cerebrospinal fluid ctDNA and metabolites are informative biomarkers for the evaluation of CNS germ cell tumors.
Takayasu T; Shah M; Dono A; Yan Y; Borkar R; Putluri N; Zhu JJ; Hama S; Yamasaki F; Tahara H; Sugiyama K; Kurisu K; Esquenazi Y; Ballester LY
Sci Rep; 2020 Aug; 10(1):14326. PubMed ID: 32868820
[TBL] [Abstract][Full Text] [Related]
23. Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies.
Momtaz P; Pentsova E; Abdel-Wahab O; Diamond E; Hyman D; Merghoub T; You D; Gasmi B; Viale A; Chapman PB
Oncotarget; 2016 Dec; 7(51):85430-85436. PubMed ID: 27863426
[TBL] [Abstract][Full Text] [Related]
24. The Utility of Liquid Biopsy in Central Nervous System Malignancies.
Nevel KS; Wilcox JA; Robell LJ; Umemura Y
Curr Oncol Rep; 2018 Jun; 20(8):60. PubMed ID: 29876874
[TBL] [Abstract][Full Text] [Related]
25. Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA.
Benešová L; Hálková T; Ptáčková R; Semyakina A; Menclová K; Pudil J; Ryska M; Levý M; Šimša J; Pazdírek F; Hoch J; Blaha M; Minárik M
World J Gastroenterol; 2019 Dec; 25(48):6939-6948. PubMed ID: 31908397
[TBL] [Abstract][Full Text] [Related]
26. Assessment of ctDNA in CSF may be a more rapid means of assessing surgical outcomes than plasma ctDNA in glioblastoma.
Li JH; He ZQ; Lin FH; Chen ZH; Yang SY; Duan H; Jiang XB; Al-Nahari F; Zhang XH; Wang JH; Zhang GH; Zhang ZF; Li C; Mou YG
Mol Cell Probes; 2019 Aug; 46():101411. PubMed ID: 31173881
[TBL] [Abstract][Full Text] [Related]
27. Clinical features and cell of origin subtyping using gene expression profiling in HIV-negative patients with primary central nervous system lymphoma.
Hilal T; Maguire A; Kosiorek HE; Rimsza LM; Rosenthal AC
Leuk Lymphoma; 2019 Dec; 60(14):3581-3583. PubMed ID: 31246148
[No Abstract] [Full Text] [Related]
28. Applications of cerebrospinal fluid circulating tumor DNA in the diagnosis of gliomas.
Zhao Z; Zhang C; Li M; Shen Y; Feng S; Liu J; Li F; Hou L; Chen Z; Jiang J; Ma X; Chen L; Yu X
Jpn J Clin Oncol; 2020 Mar; 50(3):325-332. PubMed ID: 32039443
[TBL] [Abstract][Full Text] [Related]
29. Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA.
Heger JM; Mattlener J; Schneider J; Gödel P; Sieg N; Ullrich F; Lewis R; Bucaciuc-Mracica T; Schwarz RF; Rueß D; Ruge MI; Montesinos-Rongen M; Deckert M; Blau T; Kutsch N; Balke-Want H; Weiss J; Becker K; Reinhardt HC; Hallek M; Borchmann P; von Tresckow B; Borchmann S
Blood; 2024 Feb; 143(6):522-534. PubMed ID: 37946299
[TBL] [Abstract][Full Text] [Related]
30. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R
J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585
[TBL] [Abstract][Full Text] [Related]
31. Analysis of circulating tumor DNA by targeted ultra-deep sequencing across various non-Hodgkin lymphoma subtypes.
Shin SH; Kim YJ; Lee D; Cho D; Ko YH; Cho J; Park WY; Park D; Kim SJ; Kim WS
Leuk Lymphoma; 2019 Sep; 60(9):2237-2246. PubMed ID: 30774000
[TBL] [Abstract][Full Text] [Related]
32. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
Christensen E; Birkenkamp-Demtröder K; Nordentoft I; Høyer S; van der Keur K; van Kessel K; Zwarthoff E; Agerbæk M; Ørntoft TF; Jensen JB; Dyrskjøt L
Eur Urol; 2017 Jun; 71(6):961-969. PubMed ID: 28069289
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma.
Cai Z; Chen G; Zeng Y; Dong X; Li Z; Huang Y; Xin F; Qiu L; Xu H; Zhang W; Su X; Liu X; Liu J
Clin Cancer Res; 2019 Sep; 25(17):5284-5294. PubMed ID: 31217202
[TBL] [Abstract][Full Text] [Related]
34. Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications.
Boire A; Brandsma D; Brastianos PK; Le Rhun E; Ahluwalia M; Junck L; Glantz M; Groves MD; Lee EQ; Lin N; Raizer J; Rudà R; Weller M; Van den Bent MJ; Vogelbaum MA; Chang S; Wen PY; Soffietti R
Neuro Oncol; 2019 May; 21(5):571-584. PubMed ID: 30668804
[TBL] [Abstract][Full Text] [Related]
35. Liquid Biopsy beyond Circulating Tumor Cells and Cell-Free DNA.
Junqueira-Neto S; Batista IA; Costa JL; Melo SA
Acta Cytol; 2019; 63(6):479-488. PubMed ID: 30783027
[TBL] [Abstract][Full Text] [Related]
36. Pre-operative plasma cell-free circulating tumor DNA and serum protein tumor markers as predictors of lung adenocarcinoma recurrence.
Isaksson S; George AM; Jönsson M; Cirenajwis H; Jönsson P; Bendahl PO; Brunnström H; Staaf J; Saal LH; Planck M
Acta Oncol; 2019 Aug; 58(8):1079-1086. PubMed ID: 31230502
[No Abstract] [Full Text] [Related]
37. Digital PCR-Based Detection of EGFR Mutations in Paired Plasma and CSF Samples of Lung Adenocarcinoma Patients with Central Nervous System Metastases.
Huang R; Xu X; Li D; Chen K; Zhan Q; Ge M; Zhou X; Liang X; Guan M
Target Oncol; 2019 Jun; 14(3):343-350. PubMed ID: 31161597
[TBL] [Abstract][Full Text] [Related]
38. Somatic mutations in plasma cell-free DNA are diagnostic markers for esophageal squamous cell carcinoma recurrence.
Ueda M; Iguchi T; Masuda T; Nakahara Y; Hirata H; Uchi R; Niida A; Momose K; Sakimura S; Chiba K; Eguchi H; Ito S; Sugimachi K; Yamasaki M; Suzuki Y; Miyano S; Doki Y; Mori M; Mimori K
Oncotarget; 2016 Sep; 7(38):62280-62291. PubMed ID: 27556701
[TBL] [Abstract][Full Text] [Related]
39. Diagnosis and treatment of central nervous system involvement in non-Hodgkin's lymphoma.
Bierman P; Giglio P
Hematol Oncol Clin North Am; 2005 Aug; 19(4):597-609, v. PubMed ID: 16083825
[TBL] [Abstract][Full Text] [Related]
40. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
